Skip to content
EV Therapeutics logo — Immunotherapy EVolved.

EV Therapeutics

Immunotherapy EVolved.

Founded 2020 United States San Francisco, United States 2 employees Biotechnology, Health Care

General Information

Company Name EV Therapeutics
Founded Year 2020
Location United States San Francisco, United States
Employees 2
Industries Biotechnology, Health Care
Business Model B2B, B2D
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with EV Therapeutics. To contact EV Therapeutics, visit evtherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does EV Therapeutics compare?

A PDF of EV Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting EV Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About EV Therapeutics

EV Therapeutics, with its slogan "Immunotherapy EVolved," is at the forefront of developing innovative treatments targeting advanced stage metastatic colorectal cancers. Founded in 2020 and headquartered in the United States, the company operates within the Biotechnology and Health Care industries.

The company's unique value proposition lies in its proprietary technology involving modified extracellular vesicles (mEVs). These mEVs offer a dual-action approach: they enhance tumor antigen-specific T cell infiltration and synergize with immune checkpoint blockade therapies, potentially offering significant survival benefits. Pre-clinical data indicate promising outcomes, particularly in controlling minimal residual disease and preventing cancer recurrence, positioning the therapy also as a cancer vaccine.

EV Therapeutics is currently exploring opportunities for out-licensing, co-development, and partnerships, making it an appealing target for strategic collaborations and investment.

Business keywords: Immunotherapy, Extracellular Vesicles, Advanced Stage Cancer, Metastatic Colorectal Cancer, Tumor Antigen-Specific T Cells, Tumor Microenvironment, Immune Checkpoint Blockade, Tumor-Specific T Cell Costimulation, Cancer Vaccine, Minimal Residual Disease, Oncology, Pre-clinical Data, Therapeutic Platform, Cancer Recurrence Prevention, Co-development Opportunities

Services & Products

Development of neoantigen-based immunotherapies
Production of proprietary immunotherapy vaccines
Pre-clinical efficacy testing
Combination therapy with checkpoint inhibitors

Target Customers

Cancer patients, particularly those with metastatic colorectal cancer Patients unresponsive to traditional chemotherapy Researchers and clinicians in oncology

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Spinout Undisclosed 1
University of Minnesota
01 Jul 2020

EV Therapeutics Alternatives & Competitors

View All Alternatives
EV Therapeutics vs
Memgen, Inc.
Memgen, Inc. United States

Memgen's Vision: Develop Life-Saving Cancer Immunotherapies

Venture round
7 employees
Biotechnology, Health Care
EV Therapeutics vs

Science for cure.

Grant
28 employees
Biotechnology, Health Care
EV Therapeutics vs
Pyxis Oncology
Pyxis Oncology United States

Charting a course to therapeutics for difficult-to-treat cancer.

68 employees
Biotechnology, Health Care

FAQ About EV Therapeutics

Immunotherapy EVolved.
EV Therapeutics was founded in 2020.
EV Therapeutics is headquartered in San Francisco, United States.
EV Therapeutics operates in Biotechnology and Health Care. Its work centres on Immunotherapy, Extracellular Vesicles, Advanced Stage Cancer and Metastatic Colorectal Cancer. Its customers include Cancer patients, particularly those with metastatic colorectal cancer, Patients unresponsive to traditional chemotherapy and Researchers and clinicians in oncology.
EV Therapeutics has a B2B and B2D business model. Its revenue comes from Licensing and Product Sales.
EV Therapeutics has approximately 2 employees.
EV Therapeutics has completed 1 funding round.
EV Therapeutics offers: Development of neoantigen-based immunotherapies, Production of proprietary immunotherapy vaccines, Pre-clinical efficacy testing, Combination therapy with checkpoint inhibitors.
Top alternatives and competitors to EV Therapeutics include Memgen, Inc., NEOGAP Therapeutics AB, Pyxis Oncology, CatalYm GmbH, MetiMedi Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EV Therapeutics and Memgen, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for EV Therapeutics, https://bouncewatch.com/company/ev-therapeutics, updated 30 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout